SCHEMBL4818265

SCHEMBL4818265

O=C(Nc1cc2ccc(O)cc2oc1=O)c1ccc([N+](=O)[O-])cc1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 6/20 0.75
TP53 P04637 2/20 0.71
POLB P06746 1/20 0.71
MEN1 O00255 3/20 0.66
KMT2A Q03164 3/20 0.66
CTDSP1 Q9GZU7 1/20 0.66
MAPT P10636 4/20 0.57
ALDH1A1 P00352 3/20 0.57
LMNA P02545 2/20 0.57
HTT P42858 2/20 0.57
GAA P10253 1/20 0.57
KDM4E B2RXH2 2/20 0.55
MAOB P27338 7/20 0.52
NPC1 O15118 4/20 0.52
RAB9A P51151 3/20 0.52
PKM P14618 2/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
MAOA P21397 2/20 0.49
HPGD P15428 1/20 0.47
CA12 O43570 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4820220 0.88 TP53 (0.69) ACHETP53POLBMEN1KMT2A
SCHEMBL4819228 0.83 POLB (0.77) ACHETP53POLBMEN1KMT2A
SCHEMBL4816078 0.83 TP53 (1.00) ACHETP53POLBMEN1KMT2A
SCHEMBL4819273 0.83 TP53 (1.00) ACHETP53POLBMEN1KMT2A
SCHEMBL4821425 0.81 TP53 (0.86) ACHETP53POLBMEN1KMT2A
SCHEMBL4822418 0.81 TP53 (0.74) ACHETP53POLBMEN1KMT2A
SCHEMBL4820085 0.81 TP53 (0.74) ACHETP53POLBMEN1KMT2A
SCHEMBL4820683 0.81 TP53 (0.78) ACHETP53POLBMEN1KMT2A
SCHEMBL4815694 0.81 TP53 (0.74) ACHETP53POLBMEN1KMT2A
SCHEMBL4821180 0.80 TP53 (0.79) ACHETP53POLBMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7411076-B2 such as 2-chloro-N-(7-hydroxy-2-oxo-2H-1-benzopyran-3-yl)benzamide, used for intensifying the effects of cancer therapy based on DNA injury; protein kinase inhibitors; side effect reduction INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2008-08-12 US disclosed
US-20050054717-A1 Coumarin derivative INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2005-03-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050054717-A1 Coumarin derivative ERCC2, ERCC4, DDB1 ACHE 4512/4885TP53 81/4885POLB 290/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.